EmVenio Research超额完成代谢疾病临床试验的多样性目标-动脉网

EmVenio Research exceeds diversity goals for metabolic disease clinical trial

CISION 等信源发布 2025-05-15 21:00



可切换为仅中文







New case study shows 64% of participants represent diverse populations

新案例研究表明，64%的参与者代表了多样化的人群。

DENVER

丹佛

，

May 15, 2025

2025年5月15日

/PRNewswire/ -- While clinical trials have historically struggled with participation among underrepresented populations, EmVenio Research breaks the status quo. In a recent trial for a metabolic treatment for patients with obesity, the company exceeded participation goals among diverse patients, as .

/PRNewswire/ -- 尽管临床试验历来在代表性不足的人群参与方面存在困难，EmVenio Research打破了这一现状。在近期一项针对肥胖患者的代谢治疗试验中，该公司在多样化患者群体中超额完成了参与目标，。

highlighted in its latest case study

在其最新的案例研究中被重点提及

. Patients from underrepresented populations made up 64% of the participants, far exceeding the national average of approximately 25%. This total for the trial so far includes 32% African American, 15% Hispanic and 12% Native American.

来自代表性不足人群的患者占参与者的64%，远远超过约25%的全国平均水平。截至目前，试验的参与者中包括32%的非裔美国人、15%的西班牙裔和12%的美洲原住民。

In 2020, participants in new drug trials were made up of only 8% Black individuals and 11% Hispanic individuals. Inclusivity among trial participants was a priority for this study, as obesity and diabetes rates vary greatly by race and ethnicity. Additionally, studies have shown that many individuals with obesity come from socioeconomically disadvantaged backgrounds, which often leads to limited access to clinical trials due to the significant time and commitment required from participants.

2020年，新药试验的参与者中仅有8%为黑人个体，11%为西班牙裔个体。由于肥胖和糖尿病的发病率因种族和族裔而异，因此试验参与者的包容性是本研究的优先事项。此外，研究表明，许多肥胖患者来自社会经济地位较低的背景，这通常导致他们因临床试验需要投入大量时间和精力而难以获得参与机会。

In order to enroll inclusive patient populations for this trial, EmVenio researchers recruited participants through community outreach initiatives, including free health screenings conducted at the study site. The screenings also helped improve patient comfort, as many overweight and obese patients experience psychological distress in health care settings.

为了使这项试验的患者群体具有包容性，EmVenio 的研究人员通过社区推广活动招募参与者，其中包括在研究地点进行的免费健康筛查。这些筛查还有助于提高患者的舒适度，因为许多超重和肥胖患者在医疗环境中会经历心理困扰。

EmVenio's patient-centered approach fostered strong connections between patients and researchers, increasing the likelihood of patient enrollment and retention throughout the trial..

EmVenio的以患者为中心的方法促进了患者与研究人员之间的紧密联系，提高了患者在整个试验过程中入组和留存的可能性。

'Socioeconomic barriers hinder people from participating in clinical trials and are a major contributing factor to the lack of diversity in medical research, and we helped patients to explore options for their health and receive the best possible care,' said

“社会经济障碍阻碍人们参与临床试验，是医学研究缺乏多样性的一个主要原因，我们帮助患者探索健康选择并获得尽可能最好的护理，”

Thad Wolfram

, Chief Strategy Officer of EmVenio. 'EmVenio's collaboration with fellow health care providers in these communities and our patient-first approach are what helped us generate an inclusive group of participants for this study, drawing in a more accurate representation of our nation's cultural makeup.'.

，EmVenio首席战略官。“EmVenio与这些社区内的其他医疗保健提供者的合作以及我们以患者为先的方法，帮助我们为这项研究生成了一个包容的参与者群体，更准确地代表了我国的文化构成。”

EmVenio's case study discusses the team's approach to recruit, enroll and retain patients from diverse backgrounds. To meet the sponsor's inclusivity goals for the trial, EmVenio strategically opted to conduct study visits in

EmVenio的案例研究讨论了团队招募、注册和保留不同背景患者的方法。为了满足赞助商对试验的包容性目标，EmVenio战略性地选择进行研究访问。

Oklahoma City, Oklahoma

俄克拉荷马州俄克拉荷马市

, and

，以及

Phoenix, Arizona

亚利桑那州凤凰城

. Both communities have a diverse cultural makeup of potential participants, and their respective social determinants of health revealed a robust number of patients who met the trial's requirements and criteria.

两个社区都有多样化的潜在参与者文化构成，他们各自的健康社会决定因素揭示了大量符合试验要求和标准的患者。

For information on EmVenio's inclusive, community-based approach to clinical trials, email

如需了解EmVenio包容性的、基于社区的临床试验方法，请发送电子邮件

contact@emvenio.com

。

About EmVenio Research

关于EmVenio研究

EmVenio Research, a PCM Trials Company, provides a scalable network of clinical trial sites strategically located in underrepresented communities to engage inclusive patient populations. Our extensive global network comprises highly skilled clinicians, leading principal investigators, and cutting-edge research sites, allowing us to deliver high-quality clinical research services that prioritize reducing the burden on patient participation.

EmVenio Research是一家PCM Trials公司，提供一个可扩展的临床试验站点网络，这些站点战略性地位于代表性不足的社区，以吸引包容性患者群体。我们广泛覆盖全球的网络由高技能的临床医生、领先的首席研究员和前沿的研究机构组成，使我们能够提供高质量的临床研究服务，优先减少患者参与的负担。

Visit .

访问。

emvenio.com

to learn more.

了解更多。

SOURCE EmVenio Research

来源：EmVenio Research

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？